NASDAQ · UNH
Healthcare · Medical - Healthcare Plans
$372.95
Down-$1.66 (-0.45%)
Updated Sep 24, 2026, 12:43 AM
SID Score
7.0/10
Composite research score
Smart Money
49/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
UNH closed at $372.95 after 19 trading sessions, down 7.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $381.39 | $381.39 | $372.41 | $372.95 | 4.5M |
| Sep 21, 2026 | $377.87 | $378.95 | $373.82 | $377.56 | 5.71M |
| Sep 18, 2026 | $375.29 | $378.49 | $372.42 | $376.90 | 8.62M |
| Sep 17, 2026 | $376.45 | $380.50 | $374.20 | $375.21 | 4.84M |
| Sep 16, 2026 | $375.90 | $380.22 | $373.63 | $375.26 | 4.42M |
| Sep 15, 2026 | $383.55 | $383.80 | $375.50 | $375.93 | 4.39M |
| Sep 14, 2026 | $381.44 | $386.46 | $379.2814 | $383.55 | 4.48M |
| Sep 11, 2026 | $390.42 | $391.73 | $375.90 | $379.09 | 7.48M |
| Sep 10, 2026 | $396.00 | $399.265 | $387.60 | $388.28 | 4.35M |
| Sep 9, 2026 | $405.17 | $406.53 | $378.0801 | $393.06 | 7.74M |
| Sep 8, 2026 | $392.40 | $403.885 | $390.44 | $400.84 | 7.05M |
| Sep 4, 2026 | $397.05 | $402.225 | $395.20 | $397.14 | 5.57M |
| Sep 3, 2026 | $400.02 | $405.16 | $395.3005 | $400.94 | 5.49M |
| Sep 2, 2026 | $399.27 | $401.14 | $396.51 | $399.66 | 3.27M |
| Sep 1, 2026 | $392.08 | $399.60 | $391.78 | $396.30 | 3.72M |
| Aug 31, 2026 | $393.52 | $394.49 | $387.71 | $389.41 | 5.75M |
| Aug 28, 2026 | $396.42 | $396.74 | $392.66 | $392.95 | 2.46M |
| Aug 27, 2026 | $396.87 | $399.88 | $393.77 | $395.05 | 3.67M |
| Aug 26, 2026 | $396.33 | $406.25 | $396.01 | $401.01 | 3.56M |
The latest Smart Investors Daily articles mentioning UNH.
UNH research
Company profile and research snapshot.
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | Mizuho | Outperform | — |
| Jul 21, 2026 | JP Morgan | Overweight | — |
| Jul 20, 2026 | Barclays | Overweight | — |
| Jul 17, 2026 | RBC Capital | Outperform | — |
| Jul 17, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 23, 2026
UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.
Yahoo · Sep 23, 2026
Molina Healthcare's Medicaid recovery, Medicare duals growth and contract wins support a focused turnaround story, positioning it ahead of UnitedHealth.
Yahoo · Sep 23, 2026
UnitedHealth Group has seen its share price deliver mixed results in recent years, with shorter term gains sitting alongside a longer multi year decline. That uneven share price path puts the spotlight on a simple question for investors who follow UnitedHealth Group stock: whether the current valuation is backed up by its earnings power. Over the past 3 years the stock has declined 21.4%, which puts more weight on whether the earnings profile justifies where the shares trade today. Recent...
Yahoo · Sep 22, 2026
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $372.8, denoting a -1.26% move from the preceding trading day.
Interpretive context generated from the platform’s current data sources.
UnitedHealth Group shares closed at $372.95, declining 1.02% in the most recent session, per SID market data. The stock has underperformed over the near and medium term, falling 1.89% over the past month and 7.16% over the trailing three months. Despite this recent weakness, UNH has posted a 10.69% gain over the past twelve months. Technically, the stock is trading below its 50-day moving average of $403.39, indicating sustained short-term bearish momentum, though it remains above its 200-day moving average of $346.30, suggesting the longer-term uptrend is intact. The 14-day RSI reads 39.4, approaching oversold territory but not yet triggering a classic oversold signal. UNH carries a beta of 0.432, according to Massive/Polygon data, reflecting significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 8.77 million shares, indicating robust liquidity for institutional participants.
UnitedHealth Group currently trades at a price-to-earnings ratio of 17.38, according to SID market data, positioning the managed care giant at a moderate valuation within the healthcare sector. The company's price-to-book ratio stands at 3.19, reflecting the market's premium on UNH's substantial intangible assets and franchise value. Notably, the PEG ratio registers at -1.02, per SEC filings, driven by negative projected earnings growth expectations that reflect recent headwinds facing the company's profitability trajectory. UNH offers a dividend yield of approximately 2.59%, providing income-oriented investors with a meaningful cash return component. The company's market capitalization of approximately $305 billion underscores its position as the largest publicly traded healthcare company. The combination of a below-market P/E multiple and a negative PEG ratio suggests that consensus growth estimates have deteriorated, though the valuation on a trailing earnings basis remains within historical norms for the managed care industry.
UnitedHealth Group's composite smart money score stands at 49 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction among major asset managers as documented in 13F institutional filings. Congressional trading activity is also notable, scoring 15.6 out of 25, suggesting above-average legislative interest in UNH positions. In contrast, insider sentiment scores 0.0 out of 25, and dark pool activity registers at 8.8 out of 25, contributing to the mixed composite reading. SEC Form 4 filings reveal 12 insider transactions over the past 90 days, with insiders purchasing shares in 9 transactions versus only 3 sales. This 3-to-1 buy-to-sell ratio among corporate insiders is a noteworthy data point, suggesting that executives and directors have been net buyers during the stock's recent pullback. The divergence between the low insider sentiment score and the favorable buy-sell ratio warrants monitoring as additional filings become available.
UnitedHealth Group has demonstrated a consistent pattern of exceeding analyst expectations across its most recent quarterly results, per company earnings reports. In the most recently reported quarter, UNH delivered earnings per share of $6.38 against a consensus estimate of $4.85, representing a $1.53 positive surprise, the largest beat in the trailing four-quarter period. The prior quarter saw EPS of $7.23 versus an estimated $6.56, a $0.67 upside surprise. However, the quarter ending January 2026 produced EPS of only $2.11, barely exceeding the $2.10 estimate by $0.01, reflecting meaningful earnings pressure. Analyst estimates project EPS of $6.81 for the upcoming quarter, according to consensus data. The wide variance between quarters — ranging from $2.11 to $7.23 in reported EPS — highlights significant seasonality and potential one-time items impacting quarterly comparisons. The forward earnings trajectory remains a key focus for investors evaluating the stock's current valuation.
Wall Street analysts maintain a uniformly positive stance on UnitedHealth Group, per SID consensus data. In the most recent round of coverage updates following the company's latest earnings report, all five analysts reiterated their bullish ratings. Mizuho and RBC Capital both maintained Outperform ratings on July 21 and July 17 respectively, while JP Morgan and Barclays reaffirmed Overweight ratings on July 21 and July 20. UBS reiterated its Buy rating on July 17, according to Wall Street analyst reports. Notably, none of the five analysts changed their recommendation relative to their prior ratings, signaling sustained conviction despite the stock's 7.16% decline over the past three months. The absence of any downgrades or neutral ratings among recent coverage updates suggests the sell-side views the current price weakness as a potential entry point rather than a fundamental deterioration. The consensus remains decisively bullish with no Hold or Sell ratings among the most recent analyst actions reviewed.
The latest Smart Investors Daily articles mentioning UNH.
